A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting 120 enrolled Genentech, Inc.

RandomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

Timeline

Start: 2023-08-10
Primary completion: 2027-07-31
Completion: 2027-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cevostamab	Monoclonal antibody	—	Intravenous
Subject	Elranatamab	Monoclonal antibody	—	Subcutaneous
Background	Tocilizumab	Monoclonal antibody	—	—

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Summary

Timeline

Drugs

Indications